title: Thrombopoietin is ineffective in a mouse model of motor neuron disease.
abstract: This study assessed the therapeutic efficacy of thrombopoietin (TPO) in the mouse model of ALS using two treatment paradigms. TPO was administered either daily or in 13-day treatment cycles to SOD1-G93A mice. Quantitative analysis of platelet levels, VEGF and TGF-beta1 trophic factors were assessed. The effect of TPO on disease progression was analyzed by behavioral analysis and clinical examination. TPO treatment increased levels of platelets and TGF-beta1 but not VEGF. This treatment did not affect onset or survival in these mice. Although biologically active, demonstrated by increased platelet and TGF-beta1 levels, rmTPO did not attenuate disease progression in ALS mice.
authors.affiliation: Day Neuromuscular Laboratory, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Caraganis
authors.forename: Susanna
authors.initials: S
authors.lastname: Benn
authors.forename: Merit
authors.initials: M
authors.lastname: Cudkowicz
authors.forename: Robert H
authors.initials: RH
authors.lastname: Brown
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D016472:Motor Neuron Disease / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D013926:Thrombopoietin / Q000627:therapeutic use*
chemical_list: D013926:Thrombopoietin